Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-28T00:58:26.752Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta Analysis

Published online by Cambridge University Press:  01 September 2022

A. Wadhwa ,
A. Sareen ,
C. Soeung  and
I. Penuelas-Calvo
A. Wadhwa*
Affiliation:
University of Alabama, Psychiatry, Birmingham, United States of America
A. Sareen
Affiliation:
Bronx Care Health System-Affiliated with the Icahn School of Medicine at Mount Sinai, Psychiatry, New York, United States of America
C. Soeung
Affiliation:
Bronx Care health System, Psychiatry, New York, United States of America
I. Penuelas-Calvo
Affiliation:
Fundación Jiménez Díaz, Psychiatry, Madrid, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Ziprasidone is an atypical antipsychotic that has demonstrated efficacy for the treatment of bipolar disorder and schizophrenia. There is some preliminary evidence for Ziprasidone use in children and adolescents with several open label studies and some randomized control trials, therefore it is advantageous to understand where Ziprasidone lies in the treatment algorithm of children and adolescents.

Objectives

The aim of our study is to examine the efficacy and tolerability of Ziprasidone in children and adolescents.

Methods

We conducted a literature search consisting of open label or randomized control trials (RCT) that report on Ziprasidone use in children on the PubMed database. We found 13 studies (11 open label and 2 RCT) that met our inclusion criteria. Our outcome measures included efficacy measures such as BPRS, YMRS, CGI-S and adverse effects such as weight gain, increase in BMI, QTc prolongation, sedation, dizziness and EPS.

Results

Data from thirteen studies was meta-analyzed (Total n= 560, mean age=13.16 years, male= 70.35% that reported the use of Ziprasidone in children and adolescents. We found that Ziprasidone was efficacious in children and adolescents in measures of BPRS (-13.493, p<0.05), YMRS (-14.225, p<0.05), CGI-S (-1.430, p<0.05). In measures of adverse effects, Ziprasidone was not found to cause any significant weight gain (0.164, p>0.05) or change in BMI (-0.159, p>0.05). QTc prolongation was found to be significant (13.122, p<0.05).

Conclusions

Ziprasidone is an efficacious in children and adolescent population. It does not cause significant weight gain, however QTc prolongation and sedation were found to be the most significant side effects .

Disclosure

No significant relationships.

Keywords

Ziprasidone
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S424
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.